Deal Intelligence Blog
Data-driven analysis of biotech deal trends, licensing benchmarks, and negotiation strategies from the team behind the Ambrosia Ventures deal intelligence platform.
ADC licensing deals have reached unprecedented valuations in 2026. We break down the forces behind this surge and what it means for deal teams negotiating their next partnership.
The obesity drug market has transformed biopharma deal-making. From dual incretins to oral GLP-1 formulations, we analyze how the metabolic deal landscape is evolving in 2026.
Phase 2 biotech assets consistently command 2-4x the deal values of Phase 1 programs. We explain the mechanics behind the phase transition premium and how to use it in negotiations.
Drawing from thousands of disclosed biopharma deals, we distill seven negotiation strategies that consistently produce better licensing terms for biotech companies.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 3,000+ verified biopharma transactions.
Try the Deal Calculator